Advertisement

Journal of General Internal Medicine

, Volume 15, Issue 10, pp 739–748 | Cite as

Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels

  • Richard M. HoffmanEmail author
  • David L. Clanon
  • Benjamin Littenberg
  • Joseph J. Frank
  • John C. Peirce
Review

Abstract

BACKGROUND: Prostate-specific antigen (PSA) levels between 4.0 to 10.0 ng/ml have poor specificity in prostate cancer screening, leading to unnecessary biopsies.

OBJECTIVE: To determine whether the free-to-total PSA ratio (F/T PSA) improved the diagnostic accuracy of these nonspecific PSA levels.

MEASUREMENTS AND MAIN RESULTS: Medline was searched from 1986 to 1997. Additional studies were identified from article bibliographies and by searching urology journals. Two investigators independently identified English-language studies providing F/T PSA ratio test-operating characteristics data on ≧10 cancer patients with PSA values between 2.0 and 10.0 ng/ml. Twenty-one of 90 retrieved studies met selection criteria. Two investigators independently extracted data on methodology and diagnostic performance. Investigator-selected cut points for the optimal F/T PSA ratio had a median likelihood ratio of 1.76 (interquartile range, 1.40 to 2.11) for a positive test and 0.27 (0.20 to 0.40) for a negative test. Assuming a 25% pretest probability of cancer, the posttest probabilities were 37% following a positive test and 8% following a negative test. The summary receiver operating characteristic curve showed that maintaining test sensitivity above 90% was associated with false positive rates of 60% to 90%. Methodologic problems limited the validity and generalizability of the literature.

CONCLUSIONS: A negative test reduced the posttest probability of cancer to approximately 10%. However, patients may find that this probability is not low enough to avoid undergoing prostate biopsy. The optimal F/T PSA ratio cut point and precise estimates for test specificity still need to be determined.

Key Words

prostatic neoplasm prostate-specific antigen diagnostic accuracy free PSA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer related check-up: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42–6.PubMedGoogle Scholar
  2. 2.
    American Urological Association. Early detection of prostate cancer and use of transrectal ultrasound. American Urological Association 1992 Policy Statement Book. Baltimore, Md: Williams & Wilkins; 1992.Google Scholar
  3. 3.
    PDQ. (Physician Data Query) [database online]. Bethesda, Md: National Cancer Institute: 1984 — [updated 9/99]. Screening for prostate cancer. Available from: National Cancer Institute; National Library of Medicine, Bethesda, Md: CDP Technologies, Inc., New York, NY; Lexis-Nexis, Miamisburg, Ohio.Google Scholar
  4. 4.
    American College of Physicians. Screening for prostate cancer. Ann Intern Med. 1997;126:480–4.Google Scholar
  5. 5.
    U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins; 1996.Google Scholar
  6. 6.
    Catalona WJ, Richie JP, Ahamann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–90.PubMedGoogle Scholar
  7. 7.
    Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817–21.PubMedGoogle Scholar
  9. 9.
    Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270:860–4.PubMedCrossRefGoogle Scholar
  10. 10.
    Lilja H, Christensson A, Dahlén U, et al. Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem. 1991;37:1618–25.PubMedGoogle Scholar
  11. 11.
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222–6.PubMedGoogle Scholar
  12. 12.
    Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 1990;194:755–63.PubMedCrossRefGoogle Scholar
  13. 13.
    McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995;45:729–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Lilja H. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest Suppl. 1995;220:47–56.PubMedGoogle Scholar
  15. 15.
    Leinonen J, Lövgren T, Vornanen T, Stenman UH. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α1-antichymotrypsin. Clin Chem. 1993;39:2098–103.PubMedGoogle Scholar
  16. 16.
    Christensson A, Björk T, Nilsson O, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100–5.PubMedGoogle Scholar
  17. 17.
    Abrahamsson PA, Lilja H, Oesterling JE. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am. 1997;24:353–65.PubMedCrossRefGoogle Scholar
  18. 18.
    Vessella RL, Lange PH. Issues in the assessment of prostate-specific antigen immunoassays. An update. Urol Clin North Am. 1997;24:261–8.CrossRefGoogle Scholar
  19. 19.
    Colberg JW, Smith DS, Catalona WJ. Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng/ml. J Urol. 1993;149:507–9.PubMedGoogle Scholar
  20. 20.
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Vashi AR, Oesterling JE. Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer. Mayo Clin Proc. 1997;72:337–44.PubMedCrossRefGoogle Scholar
  22. 22.
    Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate Suppl. 1996;7:64–9.PubMedCrossRefGoogle Scholar
  23. 23.
    U.S. Food and Drug Administration. Center for Devices and Radiological Health. Premarket Approval Decisions for March 1998. Available at: http://www.fda.gov:80/cdrh/pmamar98.html.Google Scholar
  24. 24.
    Catalona WJ, Partin AW, Slawin KM, et al. A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J Urol. 1997;157(suppl):111.Google Scholar
  25. 25.
    Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. New Engl J Med. 1978;299:926–30.PubMedGoogle Scholar
  26. 26.
    Jaeschke R, Guyatt G, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA. 1994;271:389–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Jaeschke R, Guyatt GH, Sackett DL. Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA. 1994;271:703–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Mulrow CD, Linn WD, Gaul MK, Pugh JA. Assessing quality of a diagnostic test evaluation. J Gen Intern Med. 1989;4:288–95.PubMedCrossRefGoogle Scholar
  29. 29.
    Irwig L, Tosteson ANA, Gatsonis C, et al. Guidelines for meta-analyses evaluating diagnostic tests. Ann Intern Med. 1994;120:667–76.PubMedGoogle Scholar
  30. 30.
    Reid MC, Lachs MS, Feinstein AR. Use of methodlogical standards in diagnostic test research. Getting better but still not good. JAMA. 1995;274:645–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Arcangeli CG, Smith DS, Ratliff TL, Catalona WJ. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol. 1997;158:2182–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology. 1996;48:33–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Jacobsen SJ, Lija H, Klee GG, Wright GL, Jr., Pettersson K, Oesterling JE. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology. 1994;44:512–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793–803.PubMedGoogle Scholar
  35. 35.
    Marley GM, Miller MC, Kattan MW, et al. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology. 1996;48:16–22.PubMedCrossRefGoogle Scholar
  36. 36.
    Stamey TA. Progress in standardization of immunoassays for prostate-specific antigen. Urol Clin North Am. 1997;24:269–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology. A basic science for clinical medicine. 2nd ed. Boston: Little, Brown; 1991.Google Scholar
  38. 38.
    Peirce JC, Cornell RG. Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making. 1993;13:141–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147:841–5.PubMedGoogle Scholar
  40. 40.
    Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316.PubMedGoogle Scholar
  41. 41.
    Littenberg B, Moses LE. Estimating diagnostic accuracy from multiple conflicting reports: a new meta-analytic method. Med Decis Making. 1993;13:313–21.PubMedCrossRefGoogle Scholar
  42. 42.
    SAS® Language: Reference. Version 6. Cary, NC: SAS Institute, Inc.; 1990.Google Scholar
  43. 43.
    Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, Baert LV. Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol. 1996;156:1042–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Froschermaier SE, Pilarsky CP, Wirth MP. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology. 1996;47:525–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem. 1997;43:1588–94.PubMedGoogle Scholar
  46. 46.
    Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, Lövgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem. 1995;41:1115–20.PubMedGoogle Scholar
  47. 47.
    Reissigl A, Klocker H, Pointner J, Ennemoser O, Falk M, Bartsch G. Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. Prostate. 1997;30:243–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Riccardo B, Alberino D, Fabrizio T, et al. Free to total prostatic specific antigen ratio as a new diagnostic tool in prostatic carcinoma. Anticancer Res. 1997;17:1297–302.PubMedGoogle Scholar
  49. 49.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate cancer and benign prostate hyperplasia. Cancer. 1997;79:104–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Tarle M, Kraljic I. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Anticancer Res. 1997;17:1531–4.PubMedGoogle Scholar
  51. 51.
    Thiel RP, Oesterling JE, Wojno KJ, et al. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology. 1996;48:45–50.PubMedCrossRefGoogle Scholar
  52. 52.
    Wolff JM, Borchers H, Effert PJ, Habib FK, Jakse G. Free-to-total prostate-specific antigen serum concentrations in patients with prostate cancer and benign prostatic hyperplasia. Br J Urol. 1996;78:409–13.PubMedGoogle Scholar
  53. 53.
    Morote J, Raventós CX, Lorente JA, et al. Measurement of free PSA in the diagnosis and staging of prostate cancer. Int J Cancer. 1997;71:756–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Murphy GP, Barren RJ, Erickson SJ, et al. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen. Cancer. 1996;78:809–18.PubMedCrossRefGoogle Scholar
  55. 55.
    Prestigiacomo AF, Stamey TA. Clinical usefulness of free and complexed PSA. Scand J Clin Lab Invest Suppl. 1995;221:32–4.PubMedGoogle Scholar
  56. 56.
    Chen YT, Luderer AA, Thiel RP, Carlson G, Cuny CL, Soriano TF. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology. 1996;47:518–24.PubMedCrossRefGoogle Scholar
  57. 57.
    Higashihara E, Nutahara K, Kojima M, et al. Significance of serum free prostate specific antigen in the screening of prostate cancer. J Urol. 1996;156:1964–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Morgan TO, McLeod DG, Leifer ES, Moul JW, Murphy GP. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate Suppl. 1996;7:58–63.PubMedCrossRefGoogle Scholar
  59. 59.
    Akdas A, Cevik I, Tarcan T, Turkeri L, Dalaman G, Emerk K. The role of free prostate-specific antigen in the diagnosis of prostate cancer. Brit J Urol. 1997;79:920–3.PubMedGoogle Scholar
  60. 60.
    Auvinen A, Tammela T, Stenman UH, et al. Screening for prostate cancer using serum prostate-specific antigen: a randomised, population-based pilot study in Finland. Br J Cancer. 1996;74:568–72.PubMedGoogle Scholar
  61. 61.
    Correale M, Pagliarulo A, Donatuti G, et al. Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE system. Int J Biol Markers. 1996;11:24–8.PubMedGoogle Scholar
  62. 62.
    Reissigl A, Pointner J, Horninger W, et al. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology. 1995;46:662–5.PubMedCrossRefGoogle Scholar
  63. 63.
    Van Cangh PJ, De Nayer P, Sauvage P, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate Suppl. 1996;7:30–4.PubMedCrossRefGoogle Scholar
  64. 64.
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology. 1995;46:779–84.PubMedCrossRefGoogle Scholar
  65. 65.
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology. 1995;46:773–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. Free and total prostate-specific antigen in a screened population. Br J Urol. 1997;79:756–62.PubMedGoogle Scholar
  67. 67.
    Morgan TO, McLeod DG, Leifer ES, Murphy GP, Moul JW. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology. 1996;48:76–80.PubMedCrossRefGoogle Scholar
  68. 68.
    Demura T, Shinohara N, Tanaka M, et al. The proportion of free to total prostate specific antigen: a method of detecting prostate carcinoma. Cancer. 1996;77:1137–43.PubMedCrossRefGoogle Scholar
  69. 69.
    Demura T, Watarai T, Togashi M, Hirano T, Ohashi N, Koyanagi T. Measurement of prostate specific antigen and γ-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer. J Urol. 1993;150:1740–5.PubMedGoogle Scholar
  70. 70.
    Kuriyama M, Takeuchi T, Shinoda I, Okana M, Nishiura T. Clinical evaluation of γ-seminoprotein in prostate cancer. Prostate. 1986;8:301–11.PubMedCrossRefGoogle Scholar
  71. 71.
    Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344:1594–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Prestigiacomo AF, Stamey TA. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol. 1997;157:189–94.PubMedCrossRefGoogle Scholar
  73. 73.
    Alivizatos G, Deliveliotis C, Mitropoulos D, et al. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Urology. 1996;48:71–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Bangma CH, Rietbergen JBW, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol. 1997;157:2191–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Björk T, Piironen T, Pettersson K, et al. Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology. 1996;48:882–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percent-age of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214–20.PubMedCrossRefGoogle Scholar
  77. 77.
    Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA. 1998;279:1542–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Egawa S, Soh S, Ohori M, et al. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan. Cancer. 1997;79:90–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Filella X, Alcover J, Molina R, et al. Clinical usefulness of free PSA fraction as an indicator of prostate cancer. Int J Cancer. 1995;63:780–4.PubMedCrossRefGoogle Scholar
  80. 80.
    Jung K, Stephan C, Lein M, et al. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin Chem. 1996;42:1026–33.PubMedGoogle Scholar
  81. 81.
    Luderer AA, Chen YT, Soriano TF, et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology. 1995;46:187–94.PubMedCrossRefGoogle Scholar
  82. 82.
    Mione R, Aimo G, Bombardieri E, et al. Preliminary results of clinical evaluation of the free/total prostate-specific antigen ratio in a multicentric study. Tumori. 1996;82:543–9.PubMedGoogle Scholar
  83. 83.
    Partin AW, Catalona WJ, Southwick PC, Subong ENP, Gasior GH, Chan DW. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996;48:55–61.PubMedCrossRefGoogle Scholar
  84. 84.
    Prestigiacomo AF, Lilja HJ, Pettersson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol. 1996;156:350–4.PubMedCrossRefGoogle Scholar
  85. 85.
    Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH Jr. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology. 1996;48:23–32.PubMedCrossRefGoogle Scholar
  86. 86.
    Van Cangh PJ, De Nayer P, De Vischer L, et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA. Urology. 1996;48:67–70.PubMedGoogle Scholar
  87. 87.
    Vashi AR, Wojno KJ, Henricks W, et al. Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 1997;49:19–27.PubMedCrossRefGoogle Scholar
  88. 88.
    Wang TJ, Hill TM, Sokoloff RL, Frankenne F, Rittenhouse HG, Wolfert RL. Dual monoclonal antibody immunoassay for free prostate-specific antigen. Prostate. 1996;28:10–6.PubMedCrossRefGoogle Scholar
  89. 89.
    Reissigl A, Klocker H, Pointner J, et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology. 1996;48:62–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Toubert ME, Guillet J, Chiron M, et al. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer. Eur J Cancer. 1996;32A:2088–93.PubMedCrossRefGoogle Scholar
  91. 91.
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452–5.PubMedCrossRefGoogle Scholar
  92. 92.
    Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol. 2000;163:806–12.PubMedCrossRefGoogle Scholar
  93. 93.
    Lachs MS, Nachamkin I, Edelstein PH, Goldman J, Feinstein AR, Schwartz JS. Spectrum bias in the evaluation of diagnostic tests: lessons from the rapid dipstick test for urinary tract infection. Ann Intern Med. 1992;117:135–40.PubMedGoogle Scholar
  94. 94.
    Stroumbakis N, Cookson MS, Reuter VE, Fair WR. Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology. 1997;49(suppl):113–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Ellis WJ, Brawer MK. Repeat prostate needle biopsy: who needs it? J Urol. 1995;153:1496–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Buck AA, Gart JJ. Comparison of a screening test and a reference test in epidemiologic studies. Indices of agreement and their relation to prevalence. Am J Epidemiol. 1966;83:586–92.PubMedGoogle Scholar
  97. 97.
    Boyko EJ, Alderman BW, Baron AE. Reference test errors bias the evaluation of diagnostic tests for ischemic heart disease. J Gen Intern Med. 1988;3:476–81.PubMedCrossRefGoogle Scholar
  98. 98.
    Nixon RG, Petteway JC, Meyer GE, Brawer MK. Comparison of three investigative assays for the free form of prostate-specific antigen. J Urol. 1997;157(suppl):255.Google Scholar
  99. 99.
    Ornstein DK, Smith DS, Rao GS, Basler JW, Ratliff TL, Catalona WJ. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol. 1997;157:2179–82.PubMedCrossRefGoogle Scholar
  100. 100.
    Nixon RG, Lilly JD, Liedtke RJ, Batjer JD. Variation of free and total prostate-specific antigen levels: The effect on percent free/total prostate-specific antigen. Arch Pathol Lab Med. 1997;121:385–91.PubMedGoogle Scholar
  101. 101.
    Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin. 1999;49:264–81.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 2000

Authors and Affiliations

  • Richard M. Hoffman
    • 1
    • 2
    Email author
  • David L. Clanon
    • 1
  • Benjamin Littenberg
    • 3
  • Joseph J. Frank
    • 4
    • 5
  • John C. Peirce
    • 4
  1. 1.the Medicine ServiceAlbuquerque Department of Veterans Affairs Medical CenterUSA
  2. 2.University of New Mexico School of MedicineAlbuquerque
  3. 3.Department of MedicineThe University of VermontBurlington
  4. 4.the Department of Medical Education and ResearchGood Samaritan Regional Medical CenterPhoenix
  5. 5.the Laboratory Sciences of ArizonaPhoenix

Personalised recommendations